StarGuide NextGen SPECT/CT for Radiology
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial evaluates the effectiveness of the StarGuide NextGen SPECT/CT system for future medical imaging use. It involves individuals already scheduled to receive a radiopharmaceutical, a special medicine used in imaging tests, as part of their regular care. Participants must be able to lie flat during the scan and provide consent to join. The study aims to determine if this new system could enhance future imaging options. As an unphased trial, it offers a unique opportunity to contribute to advancements in medical imaging technology.
What prior data suggests that the StarGuide NextGen SPECT/CT system is safe for use in radiology?
Research has shown that the StarGuide NextGen SPECT/CT system is designed for nuclear medicine imaging. This system uses advanced technology to capture clear images of the body. Generally, systems like this are easy for patients to manage.
The StarGuide system enables doctors to observe how diseases affect the body. It does not involve direct treatment, so serious side effects are uncommon. It is similar to other imaging tests, such as X-rays or MRIs.
While the system itself is new and undergoing testing, it employs imaging technology that has been used safely for many years. For specific questions, it is advisable to ask the study team for more details.12345Why are researchers excited about this trial?
Researchers are excited about the StarGuide NextGen SPECT/CT system because it offers a cutting-edge approach to nuclear medicine imaging. Unlike traditional scanners, this new system is designed to provide higher resolution images, potentially leading to more accurate diagnoses. Additionally, it aims to improve the efficiency of imaging procedures, which could mean faster and more comfortable experiences for patients. This innovative technology could significantly enhance the quality of radiological assessments, making it a promising advancement in the field.
What evidence suggests that the StarGuide NextGen SPECT/CT system is effective for radiology?
Research has shown that the StarGuide NextGen SPECT/CT system, used in this trial, provides excellent image quality. Its high ability to distinguish different energy levels allows it to produce clearer images, especially with imaging agents like 99mTc and 177Lu. Studies suggest that this system can quickly scan the whole body, potentially leading to faster and more accurate diagnoses. This advanced imaging could aid in planning better treatments in the future. Overall, the StarGuide NextGen system shows promise in improving the accuracy of medical imaging.26789
Who Is on the Research Team?
Carrie B. Hruska, PhD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This clinical trial is open to individuals who meet specific criteria set by the researchers, which are not detailed in the provided information. To participate, one would need to fit these unspecified inclusion and exclusion criteria.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo an additional scan for research purposes on the investigational StarGuide NextGen system
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- StarGuide NextGen SPECT/CT system
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
GE Healthcare
Industry Sponsor
Fotis Vlachos
GE Healthcare
Chief Marketing Officer since 2024
PhD in Molecular Biology and Biochemistry from the University of Massachusetts, MBA from the Wharton School of the University of Pennsylvania
Peter J. Arduini
GE Healthcare
Chief Executive Officer since 2022
MBA from Northwestern University, BSc in Marketing from Susquehanna University